Endotoxin removal by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma

ASAIO Journal

Volumn 44, Issue 1, 1998, Pages 54-61

  Jaber, Bertrand L ^a   Barrett, Tyler W ^a   Neto, Miguel Cendoroglo ^a   Sundaram, Sumuk ^a   King, Andrew J ^a   Pereira, Brian J G ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BACTERIA; CELL CULTURE; ENZYME IMMOBILIZATION; PHYSIOLOGICAL MODELS; POLYSTYRENES; SYNTHETIC FIBERS; TOXICITY;

ENDOTOXIN; IN VITRO HEMOPERFUSION; POLYMYXIN B CATIONIC PEPTIDE; POLYSTYRENE DERIVATIVE FIBERS; RADIOIMMUNOASSAYS;

BIOTECHNOLOGY;

CYTOKINE; ENDOTOXIN; POLYMYXIN B; POLYSTYRENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HEMOPERFUSION; HUMAN; HUMAN CELL; KLEBSIELLA PNEUMONIAE; MONONUCLEAR CELL; PLASMA; PSEUDOMONAS AERUGINOSA; RADIOIMMUNOASSAY;

EID: 0031905875     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-199801000-00012     Document Type: Article

References (67)

1. Centers for Disease Control: Increases in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 39: 31-34, 1990.
2. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113: 227-242, 1990.
3. Parrillo JE: Pathogenic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
4. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome. JAMA 273: 117-123, 1995.
5. Jaber BL, Pereira BJG: Inflammatory mediators in sepsis: rationale for extracorporeal therapies? Am I Kidney Dis 28: S35-S49, 1996.
6. Billiau A, Vandekerckhove F: Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 21: 559-573, 1991.
7. Kreger BE, Craven DE, McCabe WR: Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68: 344-355, 1980.
8. Shenep JL, Morgan KA: Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis 150: 330-388, 1984.
9. Suffredini AF, Fromm RE, Parker M, et al: The cardiovascular response of normal humans to administration of endotoxin. N Engl J Med 321: 280-287, 1989.
10. Hoffman WD, Natanson C: Endotoxin in septic shock. Anesth Analg 77: 613-624, 1993.
11. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl l Med 307: 1225-1230, 1982.
12. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102, 1991.
13. Ziegler EJ, Fisher CJJ, Sprung CL, et al: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324: 429-436, 1991.
14. Fisher CJJ, Dhainaut JFA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271: 1836-1843, 1994.
15. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 273: 934-941, 1995.
16. Morrison DC, Jacobs DM: Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13: 813-818, 1976.
17. Coyne CP, Fenwick BW: Inhibition of lipopolysaccharide-induced macrophage tumor necrosis factor-alpha synthesis by polymyxin B sulfate. Am J Veterinary Res 54: 305-314, 1993.
18. Hanasawa K, Aoki H, Yoshioka T, Matsuda K, Tani T, Kodama M: Novel mechanical assistance in the treatment of endotoxic and septicemic shock. ASAIO Trans 35: 341-343, 1989.
19. Hanasawa K, Tani T, Kodama M: New approach to endotoxin septic shock by means of Polymyxin B immobilized fiber. Surg Gynecol Obstet 168: 323-331, 1989.
20. Cheadle WC, Hanasawa K, Gallinaro RN, Nimmanwudipong T, Kodama M, Polk HC: Endotoxin filtration and immune stimulation improve survival from gram-negative sepsis. Surgery 110: 785-792, 1991.
21. Tani T, Hanasawa K, Kodama M: Usefulness of endotoxin removal from the septic blood with direct hemoperfusion using PMX-F. J Jpn Surg Soc 90: 1370-1373, 1989.
22. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 167: 412-417, 1994.
23. Kodama M, Aoki H, Tani T, Hanasawa K: Hemoperfusion using a polymyxin B immobilized fiber column for the removal of endotoxin, in Levin J, Alving CR, Munford RS, Stutz PL, (eds), Endotoxin Research Series, Amsterdam, Excerpta Medica, Amsterdam, 1993, pp. 389-398.
24. Twohy CW, Nierman ML, Duran AP: Comparison of limulus amebocyte lysates from different manufacturers. J Parenter Sci Technol 37: 93-96, 1983.
25. Thomas LL, Sturk A, Buller HR, ten Cate JW, Spijker RE, ten Cate H: Comparative investigation of a quantitative chromogenic endotoxin assay and blood cultures. Am J Clin Pathol 82: 203-206, 1984.
26. Piotrowicz Bl, McCartney A: Chromogenic limulus amoebocyte lysate assay for endotoxin: comparison of three commercial products. Med Lab Sei 44: 89-91, 1987.
27. Elin RJ, Robinson RA, Levine AS, Wolff SM: Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med 293: 521-523, 1975.
28. Roslansky PF, Novitsky TJ: Sensitivity of limulus amebocyte lysate (LAL) to LAL-reactive glucans. J Clin Microbiol 29: 2477-2483, 1991.
29. Lemke HD: Methods for the detection of endotoxins present during extracorporeal circulation. Nephrol Dial Transplant 9: 90-95, 1994.
30. Huffman WD, Danner RL, Koev LA, et al: Ability of endotoxin and heat stable components of two strains of E coli to produce lethality in canine septic shock (abstract). Crit Care Med 18: S212, 1990.
31. Raetz CRH: Biochemistry of endotoxins: Ann Rev Biochem 59: 129-170, 1990.
32. Lonnemann G, Bingel M, Floege J, Koch KM, Shaldon S, Dinarello CA: Detection of endotoxin-like interleukin-1 inducing activity during in vitro dialysis. Kidney Int 33: 29-35, 1988.
33. Sundaram S, Barrett TW, Butt NK, Porat R, King AJ, Pereira BJG: Cytokine production by human peripheral blood mononuclear cells stimulated by a Pseudomonas aeruginosa culture filtrate: role of plasma and polymyxin B. Int J Artif Organs 19: 276-283, 1996.
34. Lonnemann G, Mahiout A, Schindler R, Colton CK: Pyrogen retention by the polyamide membranes. Contrib Nephrol 96: 47-63, 1992.
35. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated Blood 78: 1275-1281, 1991.
36. van der Meer JW, Endres S, Lonnemann G, et al: Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukocyte Biol 43: 216-223, 1988.
37. Pereira BJG, Snodgrass B, Barber G, Perrella C, Chopra S, King AJ: Cytokine production during in vitro hemodialysis with new and formaldehyde- or renalin-reprocessed cellulose dialyzers. J Am Soc Nephrol 6: 1304-1308, 1995.
38. Goldie AS, Fearon KCH, Ross JA, et al: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274: 172-177, 1995.
39. Wagge A, Halstensen A, Espevik T: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1: 355-357, 1987.
40. Hoffmann JN, Faist E, Deppisch R, Hartl WH, Inthorn D: Hemofiltration in human sepsis: evidence for elimination of immunomodulatory substances. Contrib Nephrol 116: 76-79. 1995.
41. van Bommel EFH, Hesse CJ, Jutte NHPM, Zietse R, Bruining HA, Weimar W: Cytokine kinetics (TNF-alpha, IL-1 beta, IL-6) during continuous hemofiltration: a laboratory and clinical study. Contrib Nephrol 116: 62-75, 1995.
42. Storck M, Hartl WH, Zimmerer E, Inthorn D: Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure. Lancet 337: 452-455, 1991.
43. Bellomo R, Tipping P, Boyce N: Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 21: 522-526, 1993.
44. Stegmayr BG: Plasmapheresis in severe sepsis or septic shock. Blood Purif14: 94-101, 1996.
45. Bende S, Bertok L: Short communication: elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock. Circ Shock 19: 239-244, 1986.
46. Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Ann Rev Biochem 46: 723-763, 1977.
47. HsuChen CC, Feingold DS: The mechanism of polymyxin B action and selectivity toward biologic membranes. Biochemistry 12: 2105-2111, 1973.
48. Vaara M, Vaara T: Polycations as outer membrane-desorganizing agent. Antimicrob Ag Chemother 24: 114-122, 1983.
49. Lin ECC, Goldstein R, Syvanen M: Bacterial structure, in Lin ECC, Goldstein R, Syvanen M (eds), Bacteria, Plasmids, and Phages, An Introduction to Molecular Biology, Cambridge, Harvard University Press, 1984, pp. 11-33.
50. Brown MRW, Wood SM: Relation between cation and lipid content of cell walls of Pseudomonas aeruginosa, Proteus vulgaris and Klebsiella aerogenes and their sensitivity to polymyxin B and other antibacterial agents. J Pharm Pharmac 24: 215-218, 1972.
51. Schröder G, Brandenburg K, Seydel U: Polymyxin B induces permeability fluctuations in asymmetric planar lipopolysaccharide/ phospholipid bilayers. Biochemistry 31: 631-638, 1992.
52. Hancock REW: Alterations in outer membrane permeability. Ann Rev Microbiol 38: 237-264, 1984.
53. Palmer JD, Rifkind D: Neutralization of the hemodynamic effects of endotoxin by polymyxin B. Surg Cynecol Obstet 138: 755-759, 1974.
54. Duff CW, Atkins E: The inhibitory effect of polymyxin B on endotoxin-induced endogenous pyrogen production. J Immunol Methods 52: 333-340, 1982.
55. Finch RG, Snyder IS: Bacitracin, glycopeptide antibiotics, and the polymyxins, in Craig CR, Stitzel RE (eds), Modern Pharmacology, Boston, Little Brown and Company, 1994, pp. 583- 597.
56. Hanasawa K, Tani T, Kodama M, et al: Experimental study of PMX-F on its effect and biocompatibility. Jpn j Artif Organs 14: 692-695, 1985.
57. Schumann RR, Leong SR, Flaggs GW, et al: Structure and function of. lipopolysaccharide binding protein. Science 249: 1429-1431, 1990.
58. Mathison JC, Tobias PS, Wolfson E, Ulevitch RJ: Plasma lipopoly-saccharide (LPS)- binding protein, a key component in macrophage recognition of gram-negative IPS. J Immunol 149: 200-206, 1992.
59. Buret A, Cripps AW: The immunoevasive activities of Pseudomonas aeruginosa: relevance for cystic fibrosis. Am Rev Respir Dis 148: 793-805, 1993.
60. Pollack M: The virulence of Pseudomonas aeruginosa. Rev Infect Dis 6: S617-S626, 1984.
61. Staugas RE, Harvey DP, Ferrante A, Nandoskar M, Allison AC: Induction of tumor necrosis factor (TNF) and interleukin-1 (IL-I) by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation and TNF, lymphotoxin, gamma Interferon and IL-1 production in human leukocytes. Infect Immun 60: 3162-3168, 1992.
62. Ulmer AJ, Pryjma J, Tarnok Z, Ernst M, Flad HD: Inhibiting and stimulatory effects of P. aeruginosa pyocyanin in human T and B lymphocytes and human monocytes. Infect Immun 58: 808-815, 1990.
63. Chen YHU, Hancock REW, Mishell RI: Mitogenic effects of purified outer membrane proteins from pseudomonas aeruginosa. Infect Immun 28: 178-184, 1980.
64. Marra MN, Wilde CG, Collins MS, Snable JL, Scott RW: Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 144: 662-666, 1990.
65. Pereira BJG, Sundaram S, Snodgrass B, Hogan P, King A]: Lipopolysaccharide-binding protein and bactericidal/permeabilityincreasing factor in CRF and HD patients. J Am Soc Nephrol 7: 1-9, 1996.
66. Sato T, Orlovvski JP, Zborovvski M: Experimental study of extracorporeal perfusion for septic shock. ASAIO J 39: M790-M793, 1993.
67. Aoki H, Tani T, Hanasawa K, Shoji H, Kodama M: Treatment of sepsis by extracorporeal elimination of endotoxin using fiber-immobilized polymyxin B. J Jpn Surg Soc 94: 775-780, 1993.